1-4 of 4
Marnie Collins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Clinical Trials & Observations
Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman
Journal: Blood
Blood (2017) 129 (13): 1763–1767.
DOI: https://doi.org/10.1182/blood-2016-10-747170
Published: 2017
Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2014) 124 (21): 375.
DOI: https://doi.org/10.1182/blood.V124.21.375.375
Published: 2014
Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP
Journal: Blood
Blood (2012) 120 (21): 436.
DOI: https://doi.org/10.1182/blood.V120.21.436.436
Published: 2012
Journal Articles

All- trans -retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

CME
Harry J. Iland, Ken Bradstock, Shane G. Supple, Alberto Catalano, Marnie Collins, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, John Bashford, John F. Seymour
Journal: Blood
Blood (2012) 120 (8): 1570–1580.
DOI: https://doi.org/10.1182/blood-2012-02-410746
Published: 2012